The National Health Service’s (NHS) Specialist Pharmacy Service released resources for clinicians to use with patients in the discussions around switching from the reference Humira to a biosimilar.
As the United Kingdom prepares for the arrival of biosimilar adalimumab next month, government agencies are also preparing to answer many patient and physician questions about potential changes to patients’ treatment.
Last week, the National Health Service’s (NHS) Specialist Pharmacy Service released resources for clinicians to use with patients in the discussions around switching from the reference Humira to a biosimilar. The resources include a Frequently Asked Questions (FAQ) document, as well as a template of patient letter with information about what the switch might mean for them.
Click here to read about educational biosimilar resources from the FDA.
The FAQ document includes background information about biologics and biosimilars, answering questions such as “What is a biosimilar?” and “Are biosimilars safe?” It also includes the reasoning behind why NHS will be instituting the switch, stating that, “Biosimilar medicines represent very good value for the NHS since they are often much less costly than the originator medicine. The NHS is asking clinical teams, in discussion with individual patients, to use more biosimilar medicines so that the money saved can be reinvested in new medicines and treatments.”
Furthermore, the document describes the type of patient best suited to a biosimilar, namely, most patients who are currently receiving an originator biologic, even if they have just started to take that medication. However, NHS does note numerous times throughout the text that if a patient has any questions or concerns about his or her eligibility to receive the biosimilar, these should be addressed with their individual clinical team.
Finally, the documents answer questions about how the biosimilar will be administered and address any differences in the administration from that of the reference product.
This is just the latest in a string of resources centered around educating patients about biosimilars that have been released. Earlier this month, the European Medicines Agency (EMA) published new patient-focused educational materials that look to increase patient awareness about biosimilars and assure the safety and efficacy of the products to their reference biologics.
Concurrently with the release of the new materials, the EMA also released new translations of its existing biosimilar guide for healthcare providers in Dutch, French, German, Italian, Polish, Portuguese, and Spanish.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.